Handelsbanken Fonder AB lifted its stake in shares of Penumbra, Inc. (NYSE:PEN – Free Report) by 36.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,058 shares of the company’s stock after acquiring an additional 2,400 shares during the period. Handelsbanken Fonder AB’s holdings in Penumbra were worth $2,278,000 as of its most recent SEC filing.
Several other large investors have also modified their holdings of PEN. RiverPark Advisors LLC purchased a new position in shares of Penumbra during the 3rd quarter worth about $42,000. Signaturefd LLC lifted its holdings in shares of Penumbra by 27.2% during the 4th quarter. Signaturefd LLC now owns 215 shares of the company’s stock worth $54,000 after acquiring an additional 46 shares during the period. Covestor Ltd lifted its holdings in shares of Penumbra by 357.9% during the 3rd quarter. Covestor Ltd now owns 348 shares of the company’s stock worth $84,000 after acquiring an additional 272 shares during the period. Nisa Investment Advisors LLC lifted its holdings in shares of Penumbra by 496.7% during the 4th quarter. Nisa Investment Advisors LLC now owns 358 shares of the company’s stock worth $90,000 after acquiring an additional 298 shares during the period. Finally, Fifth Third Bancorp lifted its holdings in shares of Penumbra by 13.9% during the 4th quarter. Fifth Third Bancorp now owns 378 shares of the company’s stock worth $95,000 after acquiring an additional 46 shares during the period. 88.88% of the stock is currently owned by hedge funds and other institutional investors.
Insider Activity
In other news, Director Arani Bose sold 7,500 shares of the stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $250.20, for a total transaction of $1,876,500.00. Following the completion of the transaction, the director now directly owns 164,294 shares in the company, valued at approximately $41,106,358.80. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other news, Director Arani Bose sold 7,500 shares of the stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $250.20, for a total transaction of $1,876,500.00. Following the completion of the transaction, the director now directly owns 164,294 shares in the company, valued at approximately $41,106,358.80. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Don W. Kassing sold 778 shares of the stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $234.72, for a total value of $182,612.16. Following the transaction, the director now owns 1,345 shares of the company’s stock, valued at $315,698.40. The disclosure for this sale can be found here. In the last three months, insiders sold 9,648 shares of company stock worth $2,369,903. 5.30% of the stock is currently owned by insiders.
Wall Street Analysts Forecast Growth
Read Our Latest Analysis on Penumbra
Penumbra Stock Down 0.5 %
Shares of NYSE:PEN opened at $204.41 on Friday. The company has a quick ratio of 3.49, a current ratio of 6.06 and a debt-to-equity ratio of 0.02. Penumbra, Inc. has a 52-week low of $180.93 and a 52-week high of $348.67. The company has a 50 day moving average of $228.07 and a two-hundred day moving average of $231.75. The company has a market capitalization of $7.92 billion, a price-to-earnings ratio of 88.49, a price-to-earnings-growth ratio of 2.03 and a beta of 0.51.
Penumbra (NYSE:PEN – Get Free Report) last issued its quarterly earnings data on Thursday, February 22nd. The company reported $0.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.71 by $0.05. Penumbra had a net margin of 8.59% and a return on equity of 7.49%. The company had revenue of $284.68 million during the quarter, compared to the consensus estimate of $286.62 million. During the same quarter last year, the company earned $0.16 earnings per share. Penumbra’s revenue for the quarter was up 28.7% on a year-over-year basis. As a group, analysts forecast that Penumbra, Inc. will post 2.85 earnings per share for the current fiscal year.
Penumbra Profile
Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.
Featured Articles
- Five stocks we like better than Penumbra
- Manufacturing Stocks Investing
- 3 Stocks Leading the U.S. Agriculture Comeback
- What is a Secondary Public Offering? What Investors Need to Know
- How to Use Put Debit Spreads to Profit From Falling Stocks
- 3 REITs to Buy and Hold for the Long Term
- Alphabet Changes the Narrative with Its First-Ever Dividend
Want to see what other hedge funds are holding PEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Penumbra, Inc. (NYSE:PEN – Free Report).
Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.